Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC

Next Previous
X
Search
Trial Profile

A Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LAVA-1207 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man
  • Acronyms KEYNOTE-F73
  • Sponsors Lava Therapeutics

    • Most Recent Events

    • 20 Aug 2024 According to a Lava Therapeutics media release, initiated dosing in the LAVA-1207 plus pembrolizumab dose-escalation arm (KEYNOTE-F73) to potentially enhance the anti-tumor activity of LAVA-1207. This arm also utilizes the established step-dosing regimen.
    • 20 Aug 2024 According to a Lava Therapeutics media release, this trial is nnrolling in dose level 12 with no greater than Grade 2 Cytokine Release Syndrome (CRS) since the implementation of step-dosing in Q1 2024. Next data update for LAVA-1207 program expected in Q4 2024.
    • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top